Aryl spirohydantoin CGRP receptor antagonists

1. A compound of the formula I:

wherein:

B is a selected from the group consisting of:

C 3-10 cycloalkyl phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl, azepinyl, azetidinyl, benzimidazolyl, benzisoxazolyl, benzofuranyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, benzopyrazolyl, benzotriazolyl, chromanyl, cinnolinyl, dibenzofuranyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, furanyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 4-oxonaphthyridinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxopyridyl, 2-oxoquinolinyl, piperidyl, piperazinyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyridinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuranyl, tetrahydrofuryl, tetrahydroimidazopyridinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, thienyl and triazolyl,

where B is linked to A 1 via a carbon atom in B and

where B is unsubstituted or substituted with 1–5 substituents where the substituents are independently selected from R 1 , R 2 , R 3a and R 3b , wherein

R 1 , R 2 , R 3a and R 3b are independently selected from:

(1) —C 1-6 alkyl, which is unsubstituted or substituted with 1–7 substituents where the substituents are independently selected from:

(a) halo,

(b) hydroxy,

(c) —O—C 1-6 alkyl,

(d) —C 3-6 cycloalkyl,

(e) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, or morpholinyl,

 which is unsubstituted or substituted with 1–5 substituents where the substituents are independently selected from:

(i) —C 1-6 alkyl,

(ii) —O—C 1-6 alkyl,

(iii) halo,

(iv) hydroxy,

(v) trifluoromethyl, and

(vi) —OCF 3 ,

(f) —CO 2 R 9 , wherein R 9 is independently selected from:

(i) hydrogen,

(ii) —C 1-6 alkyl, which is unsubstituted or substituted with 1–6 fluoro,

(iii) —C 5-6 cycloalkyl,

(iv) benzyl, and

(v) phenyl,

(g) —NR 10 R 11 , wherein R 10 and R 11 are independently selected from:

(i) hydrogen,

(ii) —C 1-6 alkyl, which is unsubstituted or substituted with 1–6 fluoro,

(iii) —C 5-6 cycloalkyl,

(iv) benzyl,

(v) phenyl,

(vi) —COR 9 , and

(vii) —SO 2 R 12 ,

(h) —SO 2 R 12 , wherein R 12 is independently selected from:

(i) —C 1-6 alkyl, which is unsubstituted or substituted with 1–6 fluoro,

(ii) —C 5-6 cycloalkyl,

(iii) benzyl, and

(iv) phenyl,

(i) —CONR 10a R 11a , wherein R 10a and R 11a are independently selected from:

(i) hydrogen,

(ii) —C 1-6 alkyl, which is unsubstituted or substituted with 1–6 fluoro,

(iii) —C 5-6 cycloalkyl,

(iv) benzyl,

(v) phenyl,

or where R 10a and R 11a may be joined together to form a ring selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, which is unsubstituted or substituted with 1–5 substituents where the substituents are independently selected from:

 (I) —C 1-6 alkyl

 (II) —O—C 1-6 alkyl

 (III) halo

 (IV) hydroxy

 (V) phenyl, and

 (VI) benzyl,

(j) trifluoromethyl,

(k) —OCO 2 R 9 ,

(l) —(NR 10a )CO 2 R 9 ,

(m) —O(CO)NR 10a R 11a , and

(n) —(NR 9 )(CO)NR 10a R 11a ,

(2) —C 3-6 cycloalkyl, which is unsubstituted or substituted with 1–7 substituents where the substituents are independently selected from:

(a) halo,

(b) hydroxy,

(c) —O—C 1-6 alkyl,

(d) trifluoromethyl,

(e) phenyl, which is unsubstituted or substituted with 1–5 substituents where the substituents are independently selected from:

(i) —C 1-6 alkyl,

(ii) —O—C 1-6 alkyl,

(iii) halo,

(iv) hydroxy, and

(v) trifluoromethyl,

(3) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, thienyl, pyridazinyl, pyrrolidinyl, azetidinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, tetrazolyl, azepinyl, benzimidazolyl, benzopyranyl, benzofuryl, benzothiazolyl, benzoxazolyl, chromanyl, furyl, imidazolinyl, indolinyl, indolyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, isoindolinyl, tetrahydroisoquinolinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, pyrazolidinyl, pyrazolyl, pyrrolyl, quinazolinyl, tetrahydrofuryl, thiazolinyl, purinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, 1,3-dioxolanyl, oxadiazolyl, piperidinyl and morpholinyl, which is unsubstituted or substituted with 1–5 substituents where the substituents are independently selected from:

(a) —C 1-6 alkyl, which is unsubstituted or substituted with 1–6 fluoro,

(b) halo,

(c) hydroxy,

(d) —O—C 1-6 alkyl, which is unsubstituted or substituted with 1–6 fluoro,

(e) —C 3-6 cycloalkyl,

(f) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, thienyl, or morpholinyl,

 which is unsubstituted or substituted with 1–5 substituents where the substituents are independently selected from:

(i) —C 1-6 alkyl,

(ii) —O—C 1-6 alkyl,

(iii) halo,

(iv) hydroxy, and

(v) trifluoromethyl,

(g) —CO 2 R 9 ,

(h) —NR 10 R 11 ,

(i) —CONR 10 R 11 , and

(j) —SO 2 R 12 ,

(4) halo,

(5) oxo,

(6) hydroxy,

(7) —O—C 1-6 alkyl, which is unsubstituted or substituted with 1–5 halo,

(8) —CN,

(9) —CO 2 R 9 ,

(10) —NR 10 R 11 ,

(11) —SO 2 R 12 ,

(12) —CONR 10a R 11a ,

(13) —OCO 2 R 9 ,

(14) —(NR 10a )CO 2 R 9 ,

(15) —O(CO)NR 10a R 11a ,

(16) —(NR 9 )(CO)NR 10a R 11a ,

(17) —SO 2 NR 10a R 11a , and

(18) —COR 12 ;

or where R 3a and R 3b and the atom(s) to which they are attached may be joined together to form a ring selected from cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, furanyl, dihydrofuranyl, dihydropyranyl or piperazinyl, which is unsubstituted or substituted with 1–5 substituents where the substituents are independently selected from:

(a) —C 1-6 alkyl, which is unsubstituted or substituted with 1–3 substituents where the substituents are independently selected from:

(i) halo,

(ii) hydroxy,

(iii) —O—C 1-6 alkyl,

(iv) —C 3-6 cycloalkyl,

(v) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, or morpholinyl, which is unsubstituted or substituted with 1–5 substituents where the substituents are independently selected from:

 (I) —C 1-6 alkyl,

 (II) —O—C 1-6 alkyl,

 (III) halo,

 (IV) hydroxy,

 (V) trifluoromethyl, and

 (VI) —OCF 3 ,

(vi) —CO 2 R 9 ,

(vii) —NR 10 R 11 ,

(viii) —SO 2 R 12 ,

(ix) —CONR 10a R 11a , and

(x) —(NR 10a )CO 2 R 9 ,

(b) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, thienyl, pyridazinyl, pyrrolidinyl, azetidinyl, piperidinyl and morpholinyl, which is unsubstituted or substituted with 1–3 substituents where the substituents are independently selected from:

(i) —C 1-6 alkyl, which is unsubstituted or substituted with 1–6 fluoro,

(ii) halo,

(iii) hydroxy,

(iv) —O—C 1-6 alkyl, which is unsubstituted or substituted with 1–6 fluoro, and

(v) —C 3-6 cycloalkyl,

(c) halo,

(d) —SO 2 R 12 ,

(e) hydroxy,

(f) —O—C 1-6 alkyl, which is unsubstituted or substituted with 1–5 halo,

(g) —CN,

(h) —COR 12 ,

(i) —NR 10 R 11 ,

(j) —CONR 10a R 11a ,

(k) —CO 2 R 9 ,

(l) —(NR 10a )CO 2 R 9 ,

(m) —O(CO)NR 10a R 11a , and

(n) —(NR 9 )(CO)NR 10a R 11a ;

A 1 and A 2 are independently selected from:

(1) a bond,

(2) —CR 13 R 14 —, wherein R 13 and R 14 are independently selected from:

(a) hydrogen,

(b) C 1-6 alkyl, which is unsubstituted or substituted with 1–6 fluoro, and

(c) hydroxy,

(3) NR 10 —, and

(4) —CR 13 R 14 —NR 10 —,

(5) —CR 13 R 14 —CH 2 —,

(6) —CH 2 —CR 13 R 14 —,

(7) —O—CR 13 R 14 —,

(8) —CR 13 R 14 —O—, and

(9) —C≡C—,

or wherein one of A 1 and A 2 is absent;

X selected from —CO— and —SO 2 —;

R 4 is selected from:

(1) hydrogen,

(2) C 1-6 alkyl, which is unsubstituted or substituted with 1–6 fluoro,

(3) C 5-6 cycloalkyl,

(4) benzyl, and

(5) phenyl;

R 5a , R 5b and R 5c are independently selected from:

(1) hydrogen,

(2) C 1-6 alkyl,

(3) —O—C 1-6 alkyl,

(4) —OCF 3 ,

(5) trifluoromethyl,

(6) halo,

(7) hydroxy, and

(8) —CN;

R 6 is selected from:

(1) hydrogen,

(2) —C 1-6 alkyl or —C 3-6 cycloalkyl which are unsubstituted or substituted with 1–7 substituents where the substituents are independently selected from:

(a) halo,

(b) hydroxy,

(c) —O—C 1-6 alkyl,

(d) —C 3-6 cycloalkyl,

(e) phenyl, which is unsubstituted or substituted with 1–5 substituents where the substituents are independently selected from:

(i) —C 1-6 alkyl,

(ii) —O—C 1-6 alkyl,

(iii) halo,

(iv) hydroxy, and

(v) trifluoromethyl,

(f) —CO 2 R 9 ,

(g) —NR 10 R 11 ,

(h) —CONR 10 R 11 ,

(i) —SO 2 R 12 , and

(j) trifluoromethyl

(3) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, thienyl, or morpholinyl, which is unsubstituted or substituted with 1–5 substituents where the substituents are independently selected from:

(a) —C 1-6 alkyl,

(b) —O—C 1-6 alkyl,

(c) halo,

(d) hydroxy, and

(e) trifluoromethyl;

m is 1 or 2;

n is 1 or 2;

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

2. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

3. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

4. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

5. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

6. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

7. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

8. The compound of claim 1 wherein B is selected from the group consisting of: C 3-10 cycloalkyl, phenyl, napthyl, tetrahydronaphthyl, indanyl, isoquinolinyl, morpholinyl, naphthyridinyl, norbornyl, piperidyl, piperazinyl, pyrazinyl, pyridazinyl, pyridinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolidinyl, quinazolinyl, quinolinyl, quinoxalinyl, thiazolyl, and thienyl, which is unsubstituted or substituted with 1–5 substituents selected from R 1 , R 2 , R 3a and R 3b .

9. The compound of claim 1 wherein R 1 , R 2 , R 3a and R 3b are independently selected from:

(1) C 1-6 alkyl,

(2) C 3-6 cycloalkyl,

(3) —O—C 1-6 alkyl,

(4) —OCF 3 ,

(5) trifluoromethyl,

(6) halo,

(7) —CN,

(8) —COR 12 ,

(9) —CO 2 R 12 ,

(10) —CONR 10a R 11a ,

(11) phenyl, which is unsubstituted or substituted with 1–5 substituents selected from:

(a) C 1-6 alkyl,

(b) —O—C 1-6 alkyl,

(c) halo,

(d) —OH, and

(e) —CF 3 ,

(12) heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, thienyl, pyrrolidinyl, piperidinyl or morpholinyl, and which is unsubstituted or substituted with 1–5 substituents selected from:

(a) C 1-6 alkyl,

(b) —O—C 1-6 alkyl,

(c) halo,

(d) —OH, and

(e) —CF 3 .

10. A compound selected from:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

11. A pharmaceutical composition which comprises an inert carrier and the compound of claim 1 .

12. A method of treating migraine headaches or cluster headaches, said method comprising the administration, to a person in need of such treatment, of a therapeutically effective amount of the compound of claim 1 .